MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from
confidentially marketed public...
$33,008,813
Proceeds from exercise of
stock options
$38,549
Net cash provided by
financing activities
$31,052,321
Net effect of
foreign currency...
$14,086
Canceled cashflow
$1,995,041
Net increase in cash
$25,755,079
Canceled cashflow
$5,311,328
Payment of offering
transactions costs
$1,995,041
Accounts payable
$940,877
Stock-based compensation
$650,024
Prepaid expenses and
other current assets
-$137,114
Restricted stock issued for
consulting expense
$43,651
Net cash used in
operating activities
-$5,311,328
Canceled cashflow
$1,771,666
Net loss
-$6,369,652
Accrued expenses
-$458,387
Change in fair value of
warrant liability
-$254,955
Back
Back
Cash Flow
source: myfinsight.com
MAIA Biotechnology, Inc. (MAIA)
MAIA Biotechnology, Inc. (MAIA)